414 related articles for article (PubMed ID: 24895231)
21. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
22. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
23. Different carcinogenic process in cholangiocarcinoma cases epidemically developing among workers of a printing company in Japan.
Sato Y; Kubo S; Takemura S; Sugawara Y; Tanaka S; Fujikawa M; Arimoto A; Harada K; Sasaki M; Nakanuma Y
Int J Clin Exp Pathol; 2014; 7(8):4745-54. PubMed ID: 25197345
[TBL] [Abstract][Full Text] [Related]
24. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.
Wehbe H; Henson R; Meng F; Mize-Berge J; Patel T
Cancer Res; 2006 Nov; 66(21):10517-24. PubMed ID: 17079474
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma.
Boonjaraspinyo S; Wu Z; Boonmars T; Kaewkes S; Loilome W; Sithithaworn P; Nagano I; Takahashi Y; Yongvanit P; Bhudhisawasdi V
Parasitol Int; 2012 Mar; 61(1):145-50. PubMed ID: 21777692
[TBL] [Abstract][Full Text] [Related]
27. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma.
Lin KY; Ye H; Han BW; Wang WT; Wei PP; He B; Li XJ; Chen YQ
Oncogene; 2016 Jun; 35(26):3376-86. PubMed ID: 26455324
[TBL] [Abstract][Full Text] [Related]
29. Liver fluke granulin promotes extracellular vesicle-mediated crosstalk and cellular microenvironment conducive to cholangiocarcinoma.
Arunsan P; Chaidee A; Cochran CJ; Mann VH; Tanno T; Kumkhaek C; Smout MJ; Karinshak SE; Rodpai R; Sotillo J; Loukas A; Laha T; Brindley PJ; Ittiprasert W
Neoplasia; 2020 May; 22(5):203-216. PubMed ID: 32244128
[TBL] [Abstract][Full Text] [Related]
30. Small but mighty: How microRNAs drive the deadly progression of cholangiocarcinoma.
Jalil AT; Abdulhadi MA; Al-Ameer LR; Khaleel LA; Abdulameer SJ; Hadi AM; Merza MS; Zabibah RS; Ali A
Pathol Res Pract; 2023 Jul; 247():154565. PubMed ID: 37267725
[TBL] [Abstract][Full Text] [Related]
31. Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.
Lendvai G; Szekerczés T; Illyés I; Dóra R; Kontsek E; Gógl A; Kiss A; Werling K; Kovalszky I; Schaff Z; Borka K
Pathol Oncol Res; 2020 Jan; 26(1):3-15. PubMed ID: 30448973
[TBL] [Abstract][Full Text] [Related]
32. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
33. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
34. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis.
Iguchi T; Aishima S; Taketomi A; Nishihara Y; Fujita N; Sanefuji K; Sugimachi K; Yamashita Y; Maehara Y; Tsuneyoshi M
Hum Pathol; 2009 Feb; 40(2):174-80. PubMed ID: 18835624
[TBL] [Abstract][Full Text] [Related]
35. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma.
Komori J; Marusawa H; Machimoto T; Endo Y; Kinoshita K; Kou T; Haga H; Ikai I; Uemoto S; Chiba T
Hepatology; 2008 Mar; 47(3):888-96. PubMed ID: 18306229
[TBL] [Abstract][Full Text] [Related]
36. Histological features of precancerous and early cancerous lesions of biliary tract carcinoma.
Aishima S; Kubo Y; Tanaka Y; Oda Y
J Hepatobiliary Pancreat Sci; 2014 Jul; 21(7):448-52. PubMed ID: 24446428
[TBL] [Abstract][Full Text] [Related]
37. Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma.
Chaiteerakij R; Juran BD; Aboelsoud MM; Harmsen WS; Moser CD; Giama NH; Allotey LK; Mettler TA; Baichoo E; Zhang X; Therneau TM; Lazaridis KN; Roberts LR
Cancer Med; 2015 Oct; 4(10):1599-602. PubMed ID: 26276523
[TBL] [Abstract][Full Text] [Related]
38. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
39. CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.
Weng S; Janssen HLA; Zhang N; Tang W; Bai E; Yang B; Dong L
Dig Dis Sci; 2020 Apr; 65(4):1053-1063. PubMed ID: 31562609
[TBL] [Abstract][Full Text] [Related]
40. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.
Indramanee S; Sawanyawisuth K; Silsirivanit A; Dana P; Phoomak C; Kariya R; Klinhom-On N; Sorin S; Wongkham C; Okada S; Wongkham S
Sci Rep; 2019 Nov; 9(1):17266. PubMed ID: 31754244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
